FN2 Earnings Intelligence
Edwards Lifesciences Corporation earnings overview
Latest Edwards Lifesciences Corporation (EW) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Edwards Lifesciences Corporation
Edwards Lifesciences delivered a strong Q2 2026 with 12.5% YoY sales growth to $1.74 billion, beating EPS estimates by 5.0% and revenue estimates by 2.4%. The quarter was driven by broad adoption across TAVR, TMTT, and Surgical portfolios, with a competitor exit contributing to TAVR market share gains. Management raised full-year sales guidance from 8-10% to 10-11%, and the stock recovered 3.8% over subsequent sessions after an initial 1.5% dip, suggesting the market viewed the raise as well-supported despite tax and FX headwinds.
Edwards Lifesciences Corporation
The call supports a constructive but execution-dependent view: resilient TAVR demand and an expanding TMTT portfolio provide growth support, while capacity spending, patient-access investment, regulatory decisions and higher costs create execution risks.
Edwards Lifesciences Corporation
The supplied analysis supports a constructive but conditional view: strong TAVR and TMTT momentum, clinical evidence, and product expansion strengthen the growth case, while regulatory timing, reimbursement, FX, and execution risks limit certainty.
Edwards Lifesciences Corporation
The quarter supports a constructive operating trajectory: strong TAVR and TMTT performance, expanded indications and product approvals, and higher full-year guidance point to continued demand. The durability of that trajectory depends on converting approvals into procedure volume while containing acquisition, tariff and FX costs.
Edwards Lifesciences Corporation
The supplied analysis supports a constructive but conditional view: resilient TAVR and TMTT demand, broader Evoque coverage, and new valve launches could extend growth, while tariffs, integration, regulatory timing, capacity, and Japan remain material offsets.
Edwards Lifesciences Corporation
Edwards entered 2025 with reported sales growth, rapid TMTT expansion and maintained guidance. The investment case depends on converting new structural-heart products, acquisitions and early-TAVR evidence into sustained procedure growth while managing regulatory, capacity and pricing risks.
Get the EW recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.